TNP-470: an angiogenesis inhibitor in clinical development for cancer

By Kruger E.A.   Figg W.D.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1383-1396

Informa Healthcare

Access to resources Recommend Favorite

Novel pharmacological agents in clinical development for solid tumours

By Dy Grace K   Haluska Paul   Adjei Alex A  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 12, 2001-12 ,pp. : 2059-2088

Informa Healthcare

Access to resources Recommend Favorite

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

By Laird A Douglas   Cherrington Julie M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 51-64

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

By Steeghs Neeltje   Gelderblom Hans   Wessels Judith   Eskens Ferry   Bont Natasja   Nortier Johan   Guchelaar Henk-Jan  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 137-143

Springer Publishing Company

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors: Potential for the Treatment of Primary Brain Tumours

By DeMattia J.A.   Zhang W.   Couldwell W.T.  

CNS Drugs, Vol. 12, Iss. 6, 1999-12 ,pp. : 421-430

Adis International

Access to resources Recommend Favorite